These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38904339)

  • 1. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus intrapatient variability in BK virus nephropathy and chronic calcineurin toxicity in kidney transplantation.
    Turgut D; Sayin B; Soy EA; Topcu Dİ; Ozdemir BH; Haberal M
    Saudi J Kidney Dis Transpl; 2021; 32(2):348-354. PubMed ID: 35017328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
    Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
    Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies.
    Davis S; Gralla J; Klem P; Stites E; Wiseman A; Cooper JE
    Transplantation; 2020 Apr; 104(4):881-887. PubMed ID: 32224815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
    Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
    Front Immunol; 2021; 12():746013. PubMed ID: 34659243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High intra-patient variability of tacrolimus within post-operative 1 month predicted worse 1-year outcomes in pediatric liver transplant recipients.
    Chen F; Yong JK; Shen C; Zhou T; Feng M; Wan P; Luo Y; Lin H; Qian Y; Xia Q
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1017-1027. PubMed ID: 38502358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients.
    Gokoel SRM; Zwart TC; Moes DJAR; van der Boog PJM; de Fijter JW
    Ther Drug Monit; 2020 Oct; 42(5):702-709. PubMed ID: 32941396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A; Iwai T; Uchida J
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Intrapatient Variability in Tacrolimus Exposure Is Not Associated With Immune-mediated Graft Injury After Liver Transplantation.
    van der Veer MAA; Nangrahary N; Hesselink DA; Erler NS; Metselaar HJ; van Gelder T; Darwish Murad S
    Transplantation; 2019 Nov; 103(11):2329-2337. PubMed ID: 30801539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation.
    David-Neto E; Romano P; Kamada Triboni AH; Ramos F; Agena F; Almeida Rezende Ebner P; Altona M; Galante NZ; Brambate Carvalhinho Lemos F
    Transplantation; 2017 Jun; 101(6):1365-1372. PubMed ID: 27482958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
    Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
    PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation.
    Choi JS; Ko H; Kim HK; Chung C; Han A; Min SK; Ha J; Kang HG; Ha IS; Min S
    Pediatr Transplant; 2022 Sep; 26(6):e14297. PubMed ID: 35466485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients.
    Taber DJ; Hirsch J; Keys A; Su Z; McGillicuddy JW
    Ther Drug Monit; 2021 Jun; 43(3):401-407. PubMed ID: 33560095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: A retrospective cohort study.
    Hiramitsu T; Tomosugi T; Futamura K; Okada M; Nishihira M; Goto N; Ichimori T; Narumi S; Kobayashi T; Uchida K; Watarai Y
    Int Immunopharmacol; 2021 Feb; 91():107038. PubMed ID: 33388731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrapatient Variability in Tacrolimus Exposure Does Not Predict The Development of Cardiac Allograft Vasculopathy After Heart Transplant.
    Shuker N; Bouamar R; Hesselink DA; van Gelder T; Caliskan K; Manintveld OC; Balk AH; Constantinescu AA
    Exp Clin Transplant; 2018 Jun; 16(3):326-332. PubMed ID: 28969528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
    Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
    Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.